Fatal combined immune hemolytic anemia after double cord blood transplantation in imatinib-resistant CML

Bone Marrow Transplant. 2009 Sep;44(6):383-5. doi: 10.1038/bmt.2009.25. Epub 2009 Feb 16.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anemia, Hemolytic / complications
  • Anemia, Hemolytic / immunology*
  • Anemia, Hemolytic, Autoimmune / etiology*
  • Antibodies, Anti-Idiotypic / blood
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Cord Blood Stem Cell Transplantation / adverse effects*
  • Cyclosporine / therapeutic use
  • Drug Resistance, Neoplasm
  • Fatal Outcome
  • Female
  • Graft vs Host Disease / prevention & control
  • Humans
  • Imatinib Mesylate
  • Immunosuppressive Agents / therapeutic use
  • Leukemia, Myeloid, Chronic-Phase / complications
  • Leukemia, Myeloid, Chronic-Phase / therapy
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Splenectomy
  • Transfusion Reaction*
  • Transplantation Conditioning
  • Young Adult

Substances

  • Antibodies, Anti-Idiotypic
  • Antineoplastic Agents
  • Benzamides
  • Immunosuppressive Agents
  • Piperazines
  • Pyrimidines
  • Cyclosporine
  • Imatinib Mesylate